Is the business good?
How good a business is HROW?
Harrow, Inc. earns 6.6% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
6.6%
Return on invested capital · cost of capital 9.0% · 2.4 points below what the capital costs: growth destroys value
- Operating margin
- 7.3%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q1 2026
- Share count, year on year
- +3.9%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 8.9%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | 0.79% |
| FY2021 | 2.2% |
| FY2022 | 2.2% |
| FY2023 | 0.33% |
| FY2024 | 4.4% |
| FY2025 | 11% |
Details›
- Gross margin12 months to Q1 2026
- 74%
- Operating margin12 months to Q1 2026
- 7.3%
- Net margin12 months to Q1 2026
- −5.6%
- Free cash flow margin
- 5.3%
- R&D as % of revenue
- 8.9%
- Revenue, trailing twelve months
- $269M
- Free cash flow, trailing twelve months
- $14M
- Net income, trailing twelve months
- −$15M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 6.6%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #26 of 28 by Smart Score